Qube Research & Technologies Ltd - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 115 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2021. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.

Quarter-by-quarter ownership
Qube Research & Technologies Ltd ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q1 2023$332,919
+106.8%
221,946
+61.3%
0.00%0.0%
Q4 2022$160,955
+37.6%
137,568
+33.1%
0.00%0.0%
Q3 2022$117,000
-17.6%
103,322
+14.9%
0.00%0.0%
Q2 2022$142,000
-68.4%
89,960
-53.0%
0.00%
-85.7%
Q1 2021$450,000
+36.0%
191,483
+1.9%
0.01%
+40.0%
Q4 2020$331,000
+263.7%
187,964
+94.4%
0.01%
+400.0%
Q3 2020$91,000
-22.9%
96,704
-28.4%
0.00%
-50.0%
Q2 2020$118,000135,1380.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q2 2021
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$41,223,8723.66%
Raffles Associates 1,587,739$1,873,5322.48%
Defender Capital, LLC. 5,184,510$6,117,7222.22%
Prescott General Partners LLC 1,851,851$2,185,1840.14%
DCF Advisers, LLC 82,751$97,6460.05%
Beirne Wealth Consulting Services, LLC 45,000$63,4500.05%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$922,4840.02%
Fort Sheridan Advisors LLC 83,931$99,0390.02%
MAI Capital Management 954,688$1,126,5320.02%
Piscataqua Savings Bank 12,499$14,6230.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders